Plaque Psoriasis

Experts in dermatology discuss the importance of deucravacitinib being an expansion of oral treatment modalities for plaque psoriasis, as well as the long-term data.

In her interview with HCPLive, Armstrong spoke on new data presented at Fall Clinical Dermatology on bimekizumab, deucravacitinib, and upadacitinib.

An interview segment with Armstrong in which she elaborates on some of the main points made from her presentation on psoriasis treatments.

Neal Bhatia, MD, discusses the impact of treatment mode of delivery on patient adherence and treatment selection for IL-23 inhibitors for plaque psoriasis.

Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.

The sex differences, as well as other demographic differences, between GPP patients were assessed in a recent research letter.

Experts in psoriasis examine the implications of long-term data for IL-23 inhibitors, especially in patients who have not responded to initial treatment of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, comment on potential safety concerns and adverse events regarding the use of IL-23 inhibitors as well as the long-term safety and efficacy of these therapies in plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, reviews deucravacitinib as an oral treatment for moderate to severe plaque psoriasis, describing its unique mechanism of action.

Douglas DiRuggiero, DMSc, PA-C, discusses factors that contribute to switching a patient with plaque psoriasis from a topical to a systemic agent.

In a summary of a symposium from the 2021 EADV Congress, the writers describe patients’ difficulties in living with psoriasis and adhering to treatments.

A recent study found that deucravacitinib saw positive results for moderate-to-severe adult plaque psoriasis patients.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss communicating with patients about their plaque psoriasis treatment options.

George Han, MD, PhD, discusses the practical considerations of escalating treatment to the use of traditional oral systemic agents such as apremilast or methotrexate.

Matthew T. Reynolds, PA-C, reviews the route of administration and dosing frequencies of current/approved IL-23 inhibitors tildrakizumab, guselkumab, and risankizumab for treatment of plaque psoriasis.

Matthew T. Reynolds, PA-C, reviews the mechanism of action of IL-23 inhibitors for the treatment of plaque psoriasis.

Darren West, MPAS, PA-C, reviews treatment failure as criteria for advanced practice providers to utilize a step-up treatment approach.

Andrea Nguyen, MS, PA-C, reviews commonly used therapies for the initial treatment of plaque psoriasis.

Neal Bhatia, MD, provides an overview of the spectrum of disease, topical choices, and transitioning to oral medications for the treatment of plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss the current role of topical therapy and the use of non-biologic oral systemic and standard therapies for plaque psoriasis treatment.

An expert nurse practitioner and a physician assistant examine the role of collaborative care in the management of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, highlight the importance of the initial patient/provider conversation in guiding treatment of plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, discusses the various challenges care providers face when selecting treatment for patients with plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, shares his approach to building trust in the patient-provider relationship when counseling patients about treatment of plaque psoriasis.

Matthew T. Reynolds, PA-C, shares his treatment approach to plaque psoriasis based on the expanding therapeutic landscape.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, provide an overview of the pathogenesis of plaque psoriasis and how our understanding of the condition has evolved.

Neal Bhatia, MD, FAAD, reviews the clinical implications of roflumilast, a newly approved topical agent for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, provides an overview of the efficacy and safety results of the DERMIS 1 and DERMIS 2 trials for chronic plaque psoriasis treatment.

Neal Bhatia, MD, FAAD, discusses the current treatment landscape for patients with chronic plaque psoriasis, focusing specifically on PDE4 inhibitors.

Dermatology experts discuss the rapid expansion of the treatment armamentarium of plaque psoriasis and how has it shifted treatment approaches to plaque psoriasis.